# Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

> **NCT06532682** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 54 (actual)

## Conditions studied

- Diabetic Kidney Disease
- Type 1 Diabetes

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** ACE inhibitor

## Key facts

- **NCT ID:** NCT06532682
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-10-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532682, "Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06532682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*